NasdaqCM:RWLK

Stock Analysis Report

Executive Summary

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has ReWalk Robotics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.1%

RWLK

-0.4%

US Medical Equipment

1.0%

US Market


1 Year Return

-86.1%

RWLK

12.8%

US Medical Equipment

6.7%

US Market

Return vs Industry: RWLK underperformed the US Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: RWLK underperformed the US Market which returned 6.7% over the past year.


Share holder returns

RWLKIndustryMarket
7 Day-2.1%-0.4%1.0%
30 Day-11.3%-2.7%-1.8%
90 Day-35.2%-0.3%-1.8%
1 Year-86.1%-86.1%13.7%12.8%9.1%6.7%
3 Year-98.0%-98.0%70.0%64.8%46.1%36.6%
5 Year-99.6%-99.6%130.9%105.1%66.9%48.6%

Price Volatility Vs. Market

How volatile is ReWalk Robotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ReWalk Robotics undervalued based on future cash flows and its price relative to the stock market?

1.19x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate RWLK's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate RWLK's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: RWLK is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: RWLK is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate RWLK's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: RWLK is good value based on its PB Ratio (1.2x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is ReWalk Robotics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

22.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: RWLK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RWLK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RWLK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RWLK's revenue (32.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: RWLK's revenue (32.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if RWLK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ReWalk Robotics performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RWLK is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare RWLK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RWLK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: RWLK has a negative Return on Equity (-105.04%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: RWLK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: RWLK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ReWalk Robotics's financial position?


Financial Position Analysis

Short Term Liabilities: RWLK's short term assets ($28.5M) exceeds its short term liabilities ($8.4M)

Long Term Liabilities: RWLK's short term assets (28.5M) exceeds its long term liabilities (6.3M)


Debt to Equity History and Analysis

Debt Level: RWLK's debt to equity ratio (45.6%) is considered high

Reducing Debt: Insufficient data to determine if RWLK's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: RWLK has a low level of unsold assets or inventory.

Debt Coverage by Assets: RWLK's debt is covered by short term assets (assets are 3.625220x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RWLK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RWLK has sufficient cash runway for 1.387606 years if free cash flow continues to grow at historical rates of 24.4% each year.


Next Steps

Dividend

What is ReWalk Robotics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate RWLK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RWLK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RWLK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RWLK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RWLK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of ReWalk Robotics's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Larry Jasinski (62yo)

7.7yrs

Tenure

US$769,673

Compensation

Mr. Lawrence J. Jasinski, also known as Larry, BS, MBA has been the Chief Executive Officer at ReWalk Robotics Ltd. (formerly Argo Medical Technologies) since February 2012. From 2005 to 2012, Mr. Jasinski ...


CEO Compensation Analysis

Compensation vs. Market: Larry's total compensation ($USD769.67K) is about average for companies of similar size in the US market ($USD495.80K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.0yrs

Average Tenure

62yo

Average Age

Experienced Management: RWLK's management team is considered experienced (2 years average tenure).


Board Age and Tenure

5.8yrs

Average Tenure

60yo

Average Age

Experienced Board: RWLK's board of directors are considered experienced (5.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$2,33110 Jun 19
Ofir Koren
EntityIndividual
Shares358
Max PriceUS$6.52
SellUS$9429 Nov 18
Lawrence Jasinski
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15.68
Max PriceUS$6.00

Ownership Breakdown


Management Team

  • Ami Kraft (76yo)

    Executive Advisor to the CEO

    • Tenure: 2yrs
    • Compensation: US$310.00k
  • Larry Jasinski (62yo)

    CEO & Director

    • Tenure: 7.7yrs
    • Compensation: US$769.67k
  • John Hamilton (65yo)

    Consultant

    • Tenure: 2.8yrs
    • Compensation: US$258.00k
  • Miri Pariente (42yo)

    Vice President of QA & Operations

    • Tenure: 2.7yrs
  • Ori Gon (39yo)

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: US$461.95k
  • Andy Dolan

    Vice President of Marketing & Reimbursement

    • Tenure: 1.6yrs
  • Judy Kula

    Vice President of Customer Service

    • Tenure: 1.6yrs

Board Members

  • Wayne Weisman (63yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$25.00k
  • Bill Poduska (81yo)

    Independent Director

    • Tenure: 5.1yrs
    • Compensation: US$69.51k
  • Jeff Dykan (60yo)

    Independent Chairman of the Board

    • Tenure: 10.8yrs
    • Compensation: US$25.00k
  • Larry Jasinski (62yo)

    CEO & Director

    • Tenure: 7.7yrs
    • Compensation: US$769.67k
  • Pete Wehrly (60yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$61.37k
  • Yohanan Engelhardt (61yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$51.56k
  • Arik Dan (60yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$25.00k
  • Yasushi Ichiki (51yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$25.00k
  • Allen Han (25yo)

    Director

    • Tenure: 0.4yrs

Company Information

ReWalk Robotics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReWalk Robotics Ltd.
  • Ticker: RWLK
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$20.555m
  • Shares outstanding: 7.29m
  • Website: https://www.rewalk.com

Number of Employees


Location

  • ReWalk Robotics Ltd.
  • 3 Hatnufa Street
  • 6th Floor
  • Yokne'am Illit
  • 2069203
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RWLKNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDSep 2014
2RWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2014

Biography

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:10
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)